Clinical Trials Logo

Clinical Trial Details — Status: Withdrawn

Administrative data

NCT number NCT03253731
Other study ID # 170151
Secondary ID 17-N-0151
Status Withdrawn
Phase
First received
Last updated
Start date August 11, 2017
Est. completion date November 9, 2018

Study information

Verified date November 2018
Source National Institutes of Health Clinical Center (CC)
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Background:

The two hemispheres of the brain are connected. Changes in one hemisphere affect the other through this connection. Research has shown that training new skills in one hand improves the same skills for the other hand. Researchers want to learn more about how the brain works to transfer the skills to the other hand.

Objective:

To learn how changes on one side of the brain affect the other side. To study the activity of the left and right sides of the brain in healthy adults.

Eligibility:

Healthy volunteers ages 18-55 years old who are right-handed.

Design:

Participants will be screened with a medical history and physical exam. They will complete a questionnaire about their handedness. This may be done on paper or on a computer. Participants may have urine pregnancy tests.

Participants will have 2 study visits.

Participants will have a structural magnetic resonance imaging (MRI) scan. MRI uses a strong magnetic field and radio waves to take pictures of the brain. The scanner is a metal cylinder in a strong magnetic field. Participants will lie on a table that slides in and out of the cylinder.

Participants will have transcranial magnetic stimulation (TMS). Two wire coils will be placed on the scalp. A brief electrical current passes through the coil and creates a magnetic pulse that affects brain activity. Participants may be asked to tense certain muscles or do simple tasks during TMS.

Participants will have electromyography. Small sticky pad electrodes will be attached to the skin on the hands. Muscle activity will be recorded during the TMS procedure.


Description:

Objective:

The purpose of this study is to evaluate the effect of long-term potentiation (LTP)-like cortical plasticity induced by parieto-motor cortico-cortical paired associative stimulation (cc-PAS) on the contralateral hemisphere and interhemispheric interactions in normal brain using dual-site transcranial magnetic stimulation (TMS). We will explore the ipsilateral and contralateral effects of cc-PAS over the left primary motor cortex (M1). We hypothesize that the motor evoked potential (MEP) at S50 (the motor evoked potential) will change after cc-PAS in the left hemisphere, which stimulates M1 after PPC (effective cc-PAS), not only on the right first dorsal interosseous (FDI) muscle, but also the left FDI muscle.

In addition, we hypothesize that the MEP at S50 will change after cc-PAS in the left hemisphere, which stimulates PPC after M1 (ineffective cc-PAS), on the right FDI muscle but not the left FDI muscle.

Study population

We intend to study 15 healthy-volunteers to have 12 who complete the study. Subjects will complete up to one screening visit and two study visits involving two intervention.

Design

Subjects will come for one screening visit and two outpatient study visits. The screening visit and the first study visit can be performed the same day. The second study visit will be done approximately 1 week after the first one. TMS-induced electromyographic (EMG) activity of hand muscles will be recorded as MEPs. Using single TMS measure on both the left and right M1, we will measure MEPs and input-out (I-O) curve for the right and left FDI muscle and abductor digiti minimi (ADM) muscle, respectively. Using a paired-pulse TMS paradigm, interhemispheric inhibition (IHI) from the left M1 to the right M1, short-interval intracortical inhibition (SICI) and intracortical facilitation (ICF) will be measured on the left FDI and ADM muscles. Then, the subjects will undergo two plasticity induction procedures of the parieto-motor cc-PAS sessions. One of those is the hypothesized efficacious cc-PAS session and the other one is the control, a hypothesized ineffective cc-PAS session. The two sessions will be separated by approximately one week. Each session consists of 100 pairs of double stimulation to the left PPC and left M1. MEPs, I-O curve on the bilateral M1, IHI from the left M1 to the right M1, SICI and ICF will be remeasured during the 60 min after receiving cc-PAS.

Outcome measures

Primary outcome:

The primary outcome measure will be MEP amplitude from the bilateral M1 with respect to time (before, immediately and 30-45 min after intervention) after induction of cc-PAS plasticity over the left hemisphere in each session. The amplitude of MEPs on each side of M1 will be compared between before and after cc-PAS with respect to time, using ANOVA in each session.

Secondary outcome:

The degree of IHI from the left M1 to the right M1, SICI and ICF with respect to time (before, immediately and 30-45 min after intervention) will be compared by the ANOVA test. The degree of IHI and the change of IHI will be correlated with the primary outcome as measured with a correlation analysis.


Recruitment information / eligibility

Status Withdrawn
Enrollment 0
Est. completion date November 9, 2018
Est. primary completion date November 9, 2018
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 55 Years
Eligibility - INCLUSION CRITERIA:

- Between the age of 18 and 55 years

- Right-handed

- English speaking

- Ability to give informed consent

EXCLUSION CRITERIA:

- Illegal drugs use within the past 6 months based on history alone

- Abnormal findings on neurologic examination

- Have more than 7 alcoholic drinks a week in the case of a woman or 14 alcoholic drinks a week in the case of a man

- History of or current brain tumor, stroke, head trauma with loss of consciousness >few seconds, epilepsy or seizures

- History of or current episode of major depression or any major psychiatric illness (axis I disorders)

- Current diagnosis of neurologic disorder

- Presence of pacemaker, intracardiac lines, implanted pumps or stimulators, or metal objects inside the eye or skull. Dental fillings and dental braces are allowed.

- Open scalp wounds or scalp infection

- Employees and/or staff of HMCS/NINDS

- Taking benzodiazepines at the time of the entire study or within 12 days prior to the study. NOTE: Medication will not be stopped or held for participation in this study.

- Taking, at the time of the entire study or within 2 weeks prior to the study, any medication that acts as a central nervous system stimulant or that is known to lower seizure threshold, including, imipramine, amitriptyline, doxepin, nortriptyline, maprotiline, chlorpromazine, foscarnet, ganciclovir, ritonavir, amphetamines, ketamine, gamma-hydroxybutyrate (GHB), theophylline, mianserin, fluoxetine, fluvoxamine, paroxetine, sertraline, citalopram, reboxetine, venlafaxine, duloxetine, bupropion, mirtazapine, fluphenazine, pimozide, haloperidol, olanzapine, quetiapine, aripiprazole, ziprasidone, risperidone, chloroquine, mefloquine, imipenem, penicillin, ampicillin, cephalosporins, metronidazole, isoniazid, levofloxacin, cyclosporine, chlorambucil, vincristine, methotrexate, cytosine arabinoside, BCNU, lithium, antihistamines, and sympathomimetics. NOTE: Medication will not be stopped or help for participation in this study.

- Being pregnant

- You may not be eligible to have MRI or TMS in this study if:

- You have metal in your body which would make having an MRI scan unsafe, such as pacemakers, stimulators, pumps, aneurysm clips, metallic prostheses, artificial heart valves, cochlear implants or shrapnel fragments, or if you were a welder or metal worker, since you may have small metal fragments in the eye.

- You are uncomfortable in small closed spaces (you have claustrophobia) so that you would feel uncomfortable in the MRI machine.

- You are not able to lie comfortably on your back for up to 1 hour

- You have a hearing loss reported in the history or detected in the routine physical examination

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
National Institute of Neurological Disorders and Stroke (NINDS)

References & Publications (3)

Arai N, Müller-Dahlhaus F, Murakami T, Bliem B, Lu MK, Ugawa Y, Ziemann U. State-dependent and timing-dependent bidirectional associative plasticity in the human SMA-M1 network. J Neurosci. 2011 Oct 26;31(43):15376-83. doi: 10.1523/JNEUROSCI.2271-11.2011. — View Citation

Awiszus F. TMS and threshold hunting. Suppl Clin Neurophysiol. 2003;56:13-23. — View Citation

Bloom JS, Hynd GW. The role of the corpus callosum in interhemispheric transfer of information: excitation or inhibition? Neuropsychol Rev. 2005 Jun;15(2):59-71. Review. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary MEP amplitude at S50 over each side of M1 with respect to time (before, and immediately after and 30-45 min after cc-PAS over the left M1). 3 timepoints
See also
  Status Clinical Trial Phase
Completed NCT05001152 - Taste Assessment of Ozanimod Phase 1
Completed NCT05029518 - 3-Way Crossover Study to Compare the PK (Pharmokinetics) and to Evaluate the Effect of Food on the Bioavailability Phase 1
Completed NCT04493255 - A Study to Determine the Metabolism and Elimination of [14C]E7090 in Healthy Male Participants Phase 1
Completed NCT03457649 - IV Dose Study to Assess the Safety, Tolerability, PK, PD and Immunogenicity of ARGX-113 in Healthy Volunteers Phase 1
Completed NCT00995891 - Collection of Blood, Bone Marrow, and Buccal Mucosa Samples From Healthy Volunteers for Center for Human Immunology, Autoimmunity, and Inflammatory Diseases (CHI) Laboratory Research Studies
Completed NCT05050318 - Annual Study for Collection of Serum Samples in Children and Older Adults Receiving the 2021-2022 Formulations of Fluzone Quadrivalent Vaccine and Fluzone High-Dose Quadrivalent Vaccine, Respectively Phase 4
Completed NCT05043766 - Evaluation of Oral PF614 Relative to OxyContin Phase 1
Completed NCT04466748 - A Multiple Ascending Dose Pharmacology Study of Anaprazole in Healthy Chinese Subjects Phase 1
Completed NCT00746733 - Vyvanse and Adderall XR Given Alone and in Combination With Prilosec OTC Phase 1
Recruiting NCT05929651 - Study of Immunogenicity and Safety of MenQuadfi® as a Booster Vaccine in Toddlers 12 to 23 Months, Regardless of the Quadrivalent Meningococcal Conjugate Vaccine Used for Priming in Infancy Phase 4
Completed NCT05954039 - Evaluation of the Efficacy of a Dietary Supplement on Hair Loss and Hair Aspect N/A
Completed NCT05045716 - A Study of Subcutaneous Lecanemab in Healthy Participants Phase 1
Active, not recruiting NCT02747927 - Efficacy, Safety and Immunogenicity of Takeda's Tetravalent Dengue Vaccine (TDV) in Healthy Children Phase 3
Completed NCT05533801 - A Study to Demonstrate the Bioequivalence of Lecanemab Supplied in Vials and a Single-Use Auto-Injector (AI) in Healthy Participants Phase 1
Not yet recruiting NCT03931369 - Adaptation of Thirst to a Single Administration of Tolvaptan (TOLVATHIRST) Phase 2
Completed NCT03279146 - A Single Dose Study Evaluating PK of TXL Oral Formulations in Healthy Subjects Phase 1
Completed NCT06027437 - A Study to Assess the Relative Biological Availability and the Effect of Food on the Drug Levels of Danicamtiv in Healthy Adult Participants Phase 1
Recruiting NCT05619874 - Effects of Two Virtual HIFCT Programs in Adults With Abdominal Obesity N/A
Completed NCT05553418 - Investigational On-body Injector Clinical Study N/A
Completed NCT04092712 - Study Evaluating Pharmacokinetics and Mass Balance of [14C]-CTP-543 in Healthy Adult Male Volunteers Phase 1